LIBTAYO

This brand name is authorized in United States. It is also authorized in Austria, Brazil, Canada, Croatia, Cyprus, Estonia, Finland, France, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, Poland, Romania, UK.

Active ingredients

The drug LIBTAYO contains one active pharmaceutical ingredient (API):

1	Cemiplimab UNII 6QVL057INT - CEMIPLIMAB
	Cemiplimab is a fully human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the programmed cell death-1 (PD-1) receptor and blocks its interaction with its ligands PD-L1 and PD-L2. Cemiplimab potentiates T cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.
	Read more about Cemiplimab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
LIBTAYO Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FF06	Cemiplimab	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FF PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors
Discover more medicines within L01FF06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
BR	Câmara de Regulação do Mercado de Medicamentos	576719080000001
CA	Health Products and Food Branch	02487144, 02487152
EE	Ravimiamet	1799129
FI	Lääkealan turvallisuus- ja kehittämiskeskus	109464
FR	Base de données publique des médicaments	61660291
GB	Medicines & Healthcare Products Regulatory Agency	374455
IL	מִשְׂרַד הַבְּרִיאוּת	8512
IT	Agenzia del Farmaco	048070015
JP	医薬品医療機器総合機構	4291466A1024
LT	Valstybinė vaistų kontrolės tarnyba	1088128
NL	Z-Index G-Standaard, PRK	198749
PL	Rejestru Produktów Leczniczych	100422755
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W66237001
US	FDA, National Drug Code	61755-008